- Home
- FLGC vs LPCN Comparison
FLGC vs LPCN Comparison
Compare FLGC & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGC
- LPCN
- Stock Information
- Founded
- FLGC 2019
- LPCN 1997
- Country
- FLGC United States
- LPCN United States
- Employees
- FLGC N/A
- LPCN N/A
- Industry
- FLGC Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- FLGC Health Care
- LPCN Health Care
- Exchange
- FLGC Nasdaq
- LPCN Nasdaq
- Market Cap
- FLGC 15.9M
- LPCN 16.1M
- IPO Year
- FLGC 2021
- LPCN N/A
- Fundamental
- Price
- FLGC $22.50
- LPCN $2.89
- Analyst Decision
- FLGC Strong Buy
- LPCN Strong Buy
- Analyst Count
- FLGC 1
- LPCN 2
- Target Price
- FLGC $156.00
- LPCN $9.00
- AVG Volume (30 Days)
- FLGC 15.8K
- LPCN 16.1K
- Earning Date
- FLGC 08-01-2025
- LPCN 11-06-2025
- Dividend Yield
- FLGC N/A
- LPCN N/A
- EPS Growth
- FLGC N/A
- LPCN N/A
- EPS
- FLGC N/A
- LPCN N/A
- Revenue
- FLGC $52,373,000.00
- LPCN $4,208,119.00
- Revenue This Year
- FLGC N/A
- LPCN N/A
- Revenue Next Year
- FLGC $10.22
- LPCN N/A
- P/E Ratio
- FLGC N/A
- LPCN N/A
- Revenue Growth
- FLGC N/A
- LPCN N/A
- 52 Week Low
- FLGC $15.15
- LPCN $2.68
- 52 Week High
- FLGC $82.29
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- FLGC 52.11
- LPCN 39.07
- Support Level
- FLGC $21.70
- LPCN $2.86
- Resistance Level
- FLGC $22.95
- LPCN $3.00
- Average True Range (ATR)
- FLGC 1.63
- LPCN 0.12
- MACD
- FLGC 0.31
- LPCN -0.01
- Stochastic Oscillator
- FLGC 64.03
- LPCN 12.28
About FLGC Flora Growth Corp.
Flora Growth Corp is a multi-national cannabis company that manufactures and distributes consumer packaged goods, cultivates and distributes medicinal cannabis, and distributes pharmaceutical products. Its reportable segments are: the commercial and wholesale segment (FGH and Cosechemos subsidiaries) and the house of brands segment (JustCBD, Vessel, and Kasa Wholefoods Company subsidiaries). Geographically, the company generates revenue from the United States, Germany, Australia, and the United Kingdom. It generates revenue as a distributor of pharmaceutical goods, and a manufacturer and reseller of a range of cannabis-based and complementary products.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.